

Statement of Financial Results for the quarter ended 30th June 2019

Particulars	Quarter ended			Year ended
	30-Jun-19	31-Mar-19	30-Jun-18	31-Mar-19
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1 Revenue from Operations	9,404	6,880	7,989	33,016
2 Other Income	16	42	39	80
3 Total Income	9,420	6,922	8,028	33,096
4 Expenses				
(a) Cost of Materials Consumed	1,677	953	1,511	5,117
(b) Purchases of Stock-in-Trade	1,134	1,212	1,215	4,516
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	462	159	(250)	1,371
(d) Employee Benefits Expense	2,312	1,991	2,222	8,993
(e) Finance Costs	73	91	104	399
(f) Depreciation and Amortisation Expense	392	394	371	1,532
(g) Other Expenses	2,284	1,910	2,597	9,663
Total Expenses	8,334	6,710	7,770	31,591
5 Profit before tax	1,086	212	258	1,505
6 Income tax expenses				
a. Current Tax	300	18	61	284
b. Deferred Tax	(49)	40	14	140
7 Profit for the period	835	154	183	1,081
8 Other Comprehensive Income				
(i) Items that will not be reclassified to Profit or Loss	(10)	(23)	(6)	(41)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	3	8	2	14
Other Comprehensive Income Net of Tax	(7)	(15)	(4)	(27)
9 Total Comprehensive Income for the period	828	139	179	1,054
10 Paid-up Equity Share Capital (Face Value of the share - Rs. 8/- each)	1,323	1,323	1,323	1,323
11 Other Equity				14,727
12 Total Earning per Share from operations (of Rs. 8/- each) (not annualised):				
(a) Basic	5.05	0.93	1.11	6.54
(b) Diluted	5.05	0.93	1.11	6.54

Notes:

- The above results have been reviewed by the Audit Committee on July 29, 2019 and approved by the Board of Directors at its meeting held on July 30, 2019.
- The figures for the quarter ended March 31, 2019 are the balancing figures between the audited financial results for the year ended March 31, 2019 and the published unaudited financial results for the nine months ended December 31, 2018 which were subjected to a limited review.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- Effective April 1, 2019 the Company has adopted Ind AS 116 "Leases" using modified retrospective approach. This has resulted in recognising right of use assets and lease liability as on April 1, 2019. The adoption of the standard did not have any material impact to the financial results.

For RPG Life Sciences Limited

Yugal Sikri
Managing Director
Mumbai, July 30, 2019